Mirae Asset Global Investments Co., Ltd. Nurix Therapeutics, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $24 Billion
- Q4 2024
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 2,361 shares of NRIX stock, worth $29,701. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,361
Previous 2,330
1.33%
Holding current value
$29,701
Previous $52,000
15.38%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding NRIX
# of Institutions
184Shares Held
67MCall Options Held
318KPut Options Held
42.4K-
Black Rock Inc. New York, NY6.82MShares$85.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.35MShares$54.7 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.19MShares$52.7 Million6.18% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$48.8 Million0.81% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.01MShares$37.8 Million0.01% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $593M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...